• Rallybio posted a net loss of USD 8.28 million, narrowing from USD 9.44 million a year earlier.
• Operating loss improved to USD 8.73 million as total operating expenses fell 9.48% to USD 8.95 million.
• Research and development expense dropped 49.85% to USD 2.87 million, while general and administrative costs climbed 46.12% to USD 6.07 million.
• Revenue was flat at USD 212,000, while other income slid 44.38% to USD 455,000.
• Cash, cash equivalents and marketable securities totaled USD 46.8 million as of March 31, 2026; Candid terminated the merger agreement on May 3, triggering a USD 50 million termination fee paid May 4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-034580), on May 13, 2026, and is solely responsible for the information contained therein.